<p>Dyslipidemia is an alteration in lipid profiles characterized by high levels of low density lipoprotein cholesterol (LDL-C) and low levels of high density lipoprotein cholesterol (HDL-C). It is considered a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite the availability of effective lipid lowering therapies, achievement of optimal LDL-C targets remains suboptimal in real world settings due to various factors. Inclisiran is a novel small interfering RNA (siRNA) therapeutic targeting hepatic synthesis of proprotein convertase subtilisin kexin type 9 (PCSK9), and offers a different approach to lipid lowering through sustained reduction of LDL-C with a twice yearly dosing regimen. This narrative review summarizes current evidence on the mechanism of action, clinical efficacy, and safety of inclisiran, and evaluates its potential role in dyslipidemia management within the Indian context. Clinical trials have demonstrated consistent reductions in LDL-C of approximately 50% when used in addition to standard therapy, with a favorable safety profile. Its infrequent dosing schedule may improve long term adherence compared to existing therapies. However, the role of inclisiran in India is likely to remain limited to selected high risk patients due to cost, access, and healthcare system constraints. At present, it should be considered as an adjunctive option in patients who do not achieve lipid targets with conventional therapy or are unable to tolerate standard treatments.</p>